May 02, 2012 at 09:00 AM EDT
Allergan Reports First Quarter 2012 Operating Results

Allergan, Inc. (NYSE:AGN) today announced operating results for the quarter ended March 31, 2012. Allergan also announced that its Board of Directors has declared a first quarter dividend of $0.05 per share, payable on June 14, 2012 to stockholders of record on May 24, 2012.

Operating Results Attributable to Stockholders

For the quarter ended March 31, 2012:

  • Allergan reported $0.74 diluted earnings per share attributable to stockholders compared to $0.51 diluted earnings per share attributable to stockholders for the first quarter of 2011.
  • Allergan reported $0.86 non-GAAP diluted earnings per share attributable to stockholders compared to $0.77 non-GAAP diluted earnings per share attributable to stockholders for the first quarter of 2011, an 11.7 percent increase.

Product Sales

For the quarter ended March 31, 2012:

  • Allergan reported $1,365.7 million total product net sales. Total product net sales increased 9.0 percent compared to total product net sales in the first quarter of 2011. On a constant currency basis, total product net sales increased 10.4 percent compared to total product net sales in the first quarter of 2011.
    • Total specialty pharmaceuticals net sales increased 10.8 percent, or 12.2 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the first quarter of 2011.
    • Total medical devices net sales increased 0.8 percent, or 2.0 percent on a constant currency basis, compared to total medical devices net sales in the first quarter of 2011.

“In the first quarter Allergan delivered strong operating results as we continued to benefit from product approvals and operating in many growing markets,” said David E.I. Pyott, Allergan’s Chairman of the Board, President and Chief Executive Officer. “In addition, as discussed at our Research & Development Technology Review in March, we have a robust R&D pipeline that should fuel additional growth over the long-term.”

Product and Pipeline Update

During the first quarter of 2012:

  • On January 18, 2012, Senju Pharmaceutical Co., Ltd received approval from the Japanese Ministry of Health, Labour and Welfare for AIPHAGAN® P Ophthalmic Solution 0.1% for the reduction of intraocular pressure in patients with ocular hypertension and/or glaucoma. Senju possesses the rights to develop and market AIPHAGAN® P within Japan.
  • On March 12, 2012, Allergan confirmed that U.S. District Judge Andrew J. Guilford, after conducting a full trial, ruled that Merz Pharmaceuticals and Merz Aesthetics violated California’s Uniform Trade Secrets Act and issued a permanent injunction against them.
  • On March 28, 2012, Allergan announced that two Phase III clinical trials of BOTOX® (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints. Based on the results of the two Phase III clinical trials, Allergan submitted a supplemental biologics license application (sBLA) with the U.S. Food and Drug Administration (FDA) and an application with European Regulatory authorities seeking approval for the use of BOTOX® as treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Following the end of the first quarter of 2012:

  • Allergan submitted an application with Health Canada seeking approval for the use of BOTOX® as treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Outlook

For the full year of 2012, all expectations provided on February 2, 2012 remain unchanged.

For the second quarter of 2012, Allergan expects:

  • Total product net sales between $1,450 million and $1,500 million.
  • Non-GAAP diluted earnings per share attributable to stockholders between $1.04 and $1.06.

In this press release, Allergan reports certain historical and expected non-GAAP results, including earnings attributable to Allergan, Inc., non-GAAP basic and diluted earnings per share attributable to stockholders as well as non-GAAP cost of sales, non-GAAP selling, general and administrative expenses, non-GAAP research and development expenses, non-GAAP amortization of acquired intangible assets, non-GAAP impairment of intangible assets and related costs, non-GAAP restructuring charges, non-GAAP interest expense, non-GAAP other, net, non-GAAP earnings before income taxes, non-GAAP provision for income taxes, non-GAAP net earnings and non-GAAP net sales reported in constant currency. Non-GAAP financial measures are reconciled to the most directly comparable GAAP financial measure in the financial tables of this press release and the accompanying footnotes. The information that accompanies the financial tables of this press release also includes an explanation of why Allergan uses these non-GAAP financial measures, certain limitations associated with the use of these non-GAAP financial measures, the manner in which Allergan management compensates for those limitations, and the reasons why Allergan management believes that these non-GAAP financial measures provide useful information to investors.

Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to the statements by Mr. Pyott and other statements regarding product development, market potential, expected growth and regulatory approvals as well as Allergan’s earnings per share, product net sales, revenue forecasts and any other statements that refer to Allergan’s expected, estimated or anticipated future results. Because forecasts are inherently estimates that cannot be made with precision, Allergan’s performance at times differs materially from its estimates and targets, and Allergan often does not know what the actual results will be until after the end of the applicable reporting period. Therefore, Allergan will not report or comment on its progress during a current quarter except through public announcement. Any statement made by others with respect to progress during a current quarter cannot be attributed to Allergan.

All forward-looking statements in this press release reflect Allergan’s current analysis of existing trends and information and represent Allergan’s judgment only as of the date of this press release. Actual results may differ materially from current expectations based on a number of factors affecting Allergan’s businesses, including, among other things, the following: changing competitive, market and regulatory conditions; the timing and uncertainty of the results of both the research and development and regulatory processes; domestic and foreign health care and cost containment reforms, including government pricing, tax and reimbursement policies; technological advances and patents obtained by competitors; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of strategic initiatives; the results of any pending or future litigation, investigations or claims; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; and Allergan’s ability to obtain and successfully maintain a sufficient supply of products to meet market demand in a timely manner. In addition, U.S. and international economic conditions, including higher unemployment, financial hardship, consumer confidence and debt levels, taxation, changes in interest and currency exchange rates, international relations, capital and credit availability, the status of financial markets and institutions, as well as the general impact of continued economic volatility, can materially affect Allergan’s results. Therefore, the reader is cautioned not to rely on these forward-looking statements. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required to do so by law.

Additional information concerning the above-referenced risk factors and other risk factors can be found in press releases issued by Allergan, as well as Allergan’s public periodic filings with the U.S. Securities and Exchange Commission, including the discussion under the heading “Risk Factors” in Allergan’s 2011 Annual Report on Form 10-K. Copies of Allergan’s press releases and additional information about Allergan are available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 714-246-4636.

About Allergan, Inc.

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 10,000 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work.

® and ™ marks owned by Allergan, Inc.

ALLERGAN, INC.

Condensed Consolidated Statements of Earnings and

Reconciliation of Non-GAAP Adjustments

(Unaudited)

Three months ended
In millions, except per share amounts March 31, 2012 March 31, 2011
GAAP

Non-GAAP
Adjustments

Non-GAAPGAAP

Non-GAAP
Adjustments

Non-GAAP
Revenues
Product net sales $ 1,365.7 $ -- $ 1,365.7 $ 1,252.8 $ -- $ 1,252.8
Other revenues 26.2--26.218.4--18.4
1,391.9 -- 1,391.9 1,271.2 -- 1,271.2
Operating costs and expenses

Cost of sales (excludes amortization of acquired intangible assets)

195.8

(0.4

)

(a)(b)

195.4

183.3

--

183.3

Selling, general and administrative 585.1

(10.6

)

(b)(c)(d)

574.5 589.5

(55.5

)

(h)(i)(j)(k)

534.0
Research and development 225.0

(0.2

)

(d)

224.8 197.7 -- 197.7
Amortization of acquired intangible assets

31.6

(25.7

)

(e)

5.9 32.5

(26.6

)

(e)

5.9
Impairment of intangible asset -- -- -- 16.1

(16.1

)

(j)

--
Restructuring charges ------4.6

(4.6

)

(l)

--
Operating income 354.4 36.9 391.3 247.5 102.8 350.3
Non-operating income (expense)
Interest income 1.2 -- 1.2 2.3 -- 2.3
Interest expense (15.8 ) -- (15.8 ) (24.7 )

6.5

(m)

(18.2 )
Other, net (15.0)

12.5

(f)

(2.5)(9.9)

6.4

(n)(o)

(3.5)
(29.6)12.5(17.1)(32.3)12.9(19.4)
Earnings before income taxes 324.8 49.4 374.2 215.2 115.7 330.9
Provision for income taxes 94.5

13.1

(g)

107.656.4

34.1

(p)

90.5
Net earnings 230.3 36.3 266.6 158.8 81.6 240.4
Net earnings attributable to noncontrolling interest 0.5--0.50.5--0.5
Net earnings attributable to Allergan, Inc. $229.8$36.3$266.1$158.3$81.6

$239.9

Net earnings per share attributable to

Allergan, Inc. stockholders:

Basic $0.76$0.88$0.52$0.79
Diluted $0.74$0.86$0.51$0.77

Weighted average number of common

shares outstanding:

Basic

303.9 303.9 304.5 304.5

Diluted

309.7 309.7 310.8 310.8
Selected ratios as a percentage of product net sales
Cost of sales (excludes amortization of acquired intangible assets)

14.3

%

14.3

%

14.6

%

14.6

%

Selling, general and administrative 42.8 % 42.1 % 47.1 % 42.6 %
Research and development 16.5 % 16.5 % 15.8 % 15.8 %
(a) Fair market value inventory adjustment rollout of $0.3 million associated with the purchase of a distributor’s business in Russia related to Allergan’s products
(b) Expenses from changes in fair value of contingent consideration of $0.6 million and integration and transaction costs of $0.5 million associated with business combinations, consisting of cost of sales of $0.1 million and selling, general and administrative expenses of $0.4 million
(c) Aggregate charges of $9.4 million for external costs for stockholder derivative litigation associated with the U.S. Department of Justice (DOJ) settlement announced in September 2010 and other legal contingency expenses
(d) Expenses related to the realignment of various business functions of $0.4 million, consisting of selling, general and administrative expenses of $0.2 million and research and development expenses of $0.2 million
(e) Amortization of certain acquired intangible assets related to business combinations, asset acquisitions and product licenses
(f) Unrealized loss on the mark-to-market adjustment to derivative instruments
(g) Total tax effect for non-GAAP pre-tax adjustments
(h) Upfront payment of $60.0 million associated with a collaboration and co-promotion agreement with MAP Pharmaceuticals, Inc. for technology that has not achieved regulatory approval and related transaction costs of $0.6 million
(i) External costs of $1.6 million for stockholder derivative litigation associated with the DOJ settlement announced in September 2010
(j)

Fixed asset impairment of $2.3 million and a gain of $9.4 million from the substantially complete liquidation of Allergan’s investment in a foreign subsidiary included in selling, general and administrative expenses, and intangible asset impairment of $16.1 million resulting from the discontinued development of the EasybandTM Remote Adjustable Gastric Band System, a technology acquired by Allergan in the 2007 EndoArt SA acquisition

(k) Integration and transaction costs of $0.4 million associated with business combinations
(l) Net restructuring charges
(m) Non-cash interest expense associated with amortization of convertible debt discount
(n) Unrealized loss on the mark-to-market adjustment to derivative instruments of $6.9 million
(o) Gain on sale of investments of $0.5 million
(p) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions):
Tax effect
Non-GAAP pre-tax adjustments of $115.7 million $ (36.0 )
Change in estimated taxes related to uncertain tax positions and tax credits included in prior year filings

1.9

$(34.1)

“GAAP” refers to financial information presented in accordance with generally accepted accounting principles in the United States.

This press release includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission, with respect to the three months ended March 31, 2012 and March 31, 2011 and with respect to anticipated results for the second quarter and full year of 2012. Allergan believes that its presentation of non-GAAP financial measures provides useful supplementary information to investors regarding its operational performance because it enhances an investor’s overall understanding of the financial performance and prospects for the future of Allergan’s core business activities by providing a basis for the comparison of results of core business operations between current, past and future periods. The presentation of historical non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results as reported under GAAP.

In this press release, Allergan reported the non-GAAP financial measures “non-GAAP basic and diluted earnings per share attributable to Allergan, Inc. stockholders” and “non-GAAP earnings attributable to Allergan, Inc.” and its subcomponents “non-GAAP cost of sales,” “non-GAAP selling, general and administrative expenses,” “non-GAAP research and development expenses,” “non-GAAP amortization of acquired intangible assets,” “non-GAAP impairment of intangible asset,” ”non-GAAP restructuring charges,” “non-GAAP operating income,” “non-GAAP interest expense,” “non-GAAP other, net,” “non-GAAP earnings before income taxes,” “non-GAAP provision for income taxes,” and “non-GAAP net earnings.” Allergan uses non-GAAP earnings to enhance the investor’s overall understanding of the financial performance and prospects for the future of Allergan’s core business activities. Non-GAAP earnings is one of the primary indicators management uses for planning and forecasting in future periods, including trending and analyzing the core operating performance of Allergan’s business from period to period without the effect of the non-core business items indicated. Management uses non-GAAP earnings to prepare operating budgets and forecasts and to measure Allergan’s performance against those budgets and forecasts on a corporate and segment level. Allergan also uses non-GAAP earnings for evaluating management performance for compensation purposes.

Despite the importance of non-GAAP earnings in analyzing Allergan’s underlying business, the budgeting and forecasting process and designing incentive compensation, non-GAAP earnings has no standardized meaning defined by GAAP. Therefore, non-GAAP earnings has limitations as an analytical tool, and should not be considered in isolation, or as a substitute for analysis of Allergan’s results as reported under GAAP. Some of these limitations are:

  • it does not reflect cash expenditures, or future requirements, for expenditures relating to restructurings, legal settlements, and certain acquisitions, including severance and facility transition costs associated with acquisitions;
  • it does not reflect asset impairment charges or gains or losses on the disposition of assets associated with restructuring and business exit activities;
  • it does not reflect the tax benefit or tax expense associated with the items indicated;
  • it does not reflect the impact on earnings of charges or income resulting from certain matters Allergan considers not to be indicative of its on-going operations; and
  • other companies in Allergan’s industry may calculate non-GAAP earnings differently than it does, which may limit its usefulness as a comparative measure.

Allergan compensates for these limitations by using non-GAAP earnings only to supplement net earnings on a basis prepared in conformance with GAAP in order to provide a more complete understanding of the factors and trends affecting its business. Allergan strongly encourages investors to consider both net earnings and cash flows determined under GAAP as compared to non-GAAP earnings, and to perform their own analysis, as appropriate.

In this press release, Allergan also reported sales performance using the non-GAAP financial measure of constant currency sales. Constant currency sales represent current period reported sales adjusted for the translation effect of changes in average foreign exchange rates between the current period and the corresponding period in the prior year. Allergan calculates the currency effect by comparing adjusted current period reported amounts, calculated using the monthly average foreign exchange rates for the corresponding period in the prior year, to the actual current period reported amounts. Management refers to growth rates at constant currency so that sales results can be viewed without the impact of changing foreign currency exchange rates, thereby facilitating period-to-period comparisons of Allergan’s sales. Generally, when the dollar either strengthens or weakens against other currencies, the growth at constant currency rates will be higher or lower, respectively, than growth reported at actual exchange rates.

Reporting sales performance using constant currency sales has the limitation of excluding currency effects from the comparison of sales results over various periods, even though the effect of changing foreign currency exchange rates has an actual effect on Allergan’s operating results. Investors should consider these effects in their overall analysis of Allergan’s operating results.

ALLERGAN, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

March 31,

December 31,

in millions

2012

2011

Assets
Cash and equivalents $ 2,291.7 $ 2,406.1
Short-term investments 349.8 179.9
Trade receivables, net 855.7 730.6
Inventories 261.9 249.7
Other current assets 479.5482.0
Total current assets 4,238.6 4,048.3
Property, plant and equipment, net 807.0 807.0
Intangible assets, net 1,144.3 1,165.2
Goodwill 2,097.3 2,088.4
Other noncurrent assets 397.0399.7
Total assets$8,684.2$8,508.6
Liabilities and equity
Notes payable $ 87.7 $ 83.9
Accounts payable 203.0 200.4
Other accrued expenses 678.1670.7
Total current liabilities 968.8 955.0
Long-term debt 1,514.7 1,515.4
Other liabilities 719.8 705.8
Equity:
Allergan, Inc. stockholders’ equity 5,458.6 5,309.6
Noncontrolling interest 22.322.8
Total equity5,480.95,332.4
Total liabilities and equity$8,684.2$

8,508.6

DSO5748
DOH122125
Cash and equivalents and short-term investments$2,641.5$2,586.0
Total notes payable and long-term debt(1,602.4)(1,599.3)
Cash and short-term investments, net of debt$1,039.1$986.7
Debt-to-capital percentage22.6%23.1%

ALLERGAN, INC.

Reconciliation of Non-GAAP Earnings and Diluted Earnings Per Share Attributable to Allergan, Inc. Stockholders

(Unaudited)

In millions, except per share amounts

Three months ended

March 31,

March 31,

2012

2011

Net earnings attributable to Allergan, Inc. $ 229.8 $ 158.3
Non-GAAP pre-tax adjustments:

Fair market value inventory adjustment rollout associated with the purchase of a distributor’s business in Russia

0.3

--

Expenses from changes in fair value of contingent consideration and integration and transaction costs associated with business combinations

1.1

0.4

Aggregate charges for external costs for stockholder derivative litigation associated with the DOJ settlement and other legal contingency expenses

9.4

1.6

Expenses related to the realignment of various business functions 0.4 --
Amortization of acquired intangible assets 25.7 26.6
Unrealized loss on derivative instruments 12.5 6.9
Upfront payment associated with a collaboration and co-promotion agreement with MAP Pharmaceuticals, Inc. for technology that has not achieved regulatory approval and related transaction costs

--

60.6

Cumulative net expense for fixed asset impairment, a gain from the substantially complete liquidation of Allergan’s investment in a foreign subsidiary and intangible asset impairment resulting from the discontinued development of the EasybandTM Remote Adjustable Gastric Band System

--

9.0

Net restructuring charges -- 4.6
Non-cash interest expense associated with amortization of convertible debt discount -- 6.5
Gain on sale of investments --(0.5)
279.2 274.0
Tax effect for above items (13.1 ) (36.0 )
Change in estimated taxes related to uncertain tax positions and tax credits included in prior year filings

--

1.9

Non-GAAP earnings attributable to Allergan, Inc.

$

266.1

$

239.9

Weighted average number of shares outstanding 303.9 304.5

Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price

5.8

5.1

Dilutive effect of assumed conversion of convertible notes outstanding --1.2
309.7310.8
Diluted earnings per share attributable to Allergan, Inc. stockholders $ 0.74 $ 0.51
Non-GAAP earnings per share adjustments:
Aggregate charges for external costs for stockholder derivative litigation associated with the DOJ settlement and other legal contingency expenses

0.03

--

Amortization of acquired intangible assets 0.06 0.06
Unrealized loss on derivative instruments 0.03 0.01
Upfront payment associated with a collaboration and co-promotion agreement with MAP Pharmaceuticals, Inc. for technology that has not achieved regulatory approval and related transaction costs

--

0.12

Cumulative net expense for fixed asset impairment, a gain from the substantially complete liquidation of Allergan’s investment in a foreign subsidiary and intangible asset impairment resulting from the discontinued development of the EasybandTM Remote Adjustable Gastric Band System

--

0.03

Net restructuring charges -- 0.02
Non-cash interest expense associated with amortization of convertible debt discount -- 0.01
Change in estimated taxes related to uncertain tax positions and tax credits included in prior year filings

--

0.01

Non-GAAP diluted earnings per share attributable to Allergan, Inc. stockholders $0.86$0.77
Year over year change 11.7%

ALLERGAN, INC.

Supplemental Non-GAAP Information

(Unaudited)

Three months ended

March 31,

March 31,

$ change in net sales

Percent change in net sales

2012

2011

Total

Performance

Currency

Total

Performance

Currency

in millions

Eye Care Pharmaceuticals $ 652.5 $ 591.9 $ 60.6 $ 71.1 $ (10.5 ) 10.2 % 12.0 % (1.8 )%
Botox/Neuromodulator 398.9 364.5 34.4 38.3 (3.9 ) 9.4 % 10.5 % (1.1 )%
Skin Care 75.6 58.7 16.9 16.9 -- 28.8 % 28.8 % --
Urologics 12.513.3(0.8)(0.8)-- (6.0 )% (6.0 )% --
Total Specialty Pharmaceuticals

1,139.5

1,028.4

111.1

125.5

(14.4

)

10.8

%

12.2

%

(1.4

)%

Breast Aesthetics 98.4 84.1 14.3 15.5 (1.2 ) 17.0 % 18.4 % (1.4 )%
Obesity Intervention 44.0 52.1 (8.1 ) (7.8 ) (0.3 ) (15.5 )% (15.0 )% (0.5 )%
Facial Aesthetics 83.888.2(4.4)(3.1)(1.3) (5.0 )% (3.5 )% (1.5 )%
Total Medical Devices 226.2224.41.84.6(2.8) 0.8 % 2.0 % (1.2 )%
Product net sales $1,365.7$1,252.8$112.9$130.1$(17.2) 9.0 % 10.4 % (1.4 )%
Selected Product Net Sales (a):
Alphagan P, Alphagan, and

Combigan

$

112.2

$

100.2

$

12.0

$

13.5

$

(1.5

)

11.9

%

13.5

%

(1.6

)%

Lumigan Franchise 150.2 142.2 8.0 10.6 (2.6 ) 5.6 % 7.5 % (1.9 )%
Restasis 185.7 161.4 24.3 25.1 (0.8 ) 15.1 % 15.5 % (0.4 )%
Sanctura Franchise 12.5 13.3 (0.8 ) (0.8 ) -- (6.0 )% (6.0 )% --
Latisse 23.0 25.3 (2.3 ) (2.2 ) (0.1 ) (8.9 )% (8.8 )% (0.1 )%
Domestic 60.5 % 60.9 %
International 39.5 % 39.1 %
(a) Percentage change in selected product net sales is calculated on amounts reported to the nearest whole dollar.

ALLERGAN, INC.

Reconciliation of GAAP Diluted Earnings Per Share Expectations

To Non-GAAP Diluted Earnings Per Share Expectations

(Unaudited)

Second Quarter 2012
Low High
GAAP diluted earnings per share attributable to Allergan, Inc. stockholders expectations (a) $ 0.98 $ 1.00
Amortization of acquired intangible assets 0.060.06
Non-GAAP diluted earnings per share expectations $1.04$1.06
Full Year 2012
Low High
GAAP diluted earnings per share attributable to Allergan, Inc. stockholders expectations (a) $ 3.83 $ 3.89
Aggregate charges for external costs for stockholder derivative litigation associated with the DOJ settlement and other legal contingency expenses

0.03

0.03

Amortization of acquired intangible assets 0.24 0.24
Unrealized loss on derivative instruments 0.030.03
Non-GAAP diluted earnings per share expectations $4.13$4.19
(a) GAAP diluted earnings per share expectations exclude any potential impact of future unrealized gains or losses on derivative instruments, changes in contingent consideration, restructuring charges and stockholder derivative litigation costs related to the 2010 DOJ settlement and other legal contingency expenses that may occur but that are not currently known or determinable.

Contacts:

Allergan Contacts
Jim Hindman (714) 246-4636 (investors)
Joann Bradley (714) 246-4766 (investors)
David Nakasone (714) 246-6376 (investors)
Bonnie Jacobs (714) 246-5134 (media)
Cathy Taylor (714) 246-5551 (media)
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here